Navigation Links
Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
Date:12/16/2008

l at IR@novacea.com or by telephone at (650) 228-1800. Investors and security holders are urged to read the proxy statement/prospectus/information statement and the other relevant materials before making any voting or investment decision with respect to the proposed transaction.

Novacea and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from its stockholders in favor of the proposed transaction. Information about the directors and executive officers of Novacea and their respective interests in the proposed transaction is available in the proxy statement/prospectus/information statement.

SafeHarbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept and Novacea disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of potential U.S. Food and Drug Administration (FDA) approval of Intermezzo(R); and the expected timing of commercialization and launch of Intermezzo(R); and the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, failure of Novacea stockholders to approve the merger; Novacea or Transcept inability to satisfy the conditions of the merger, or that the merger is otherwise delayed or ultimately not consummated; the rates of use of Transcept and Novacea cash and cash equivalents prior to the closing of
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Reportlinker.com announces that a new market research report ... Global Biotechnology Reagents Industry ... the worldwide markets for Biotechnology Reagents in US$ ... Reagents, DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, Flow Cytometry ...
... licensed within the next 4 years, as manufacturers are ... candidates in collaboration with health authorities and developing countries ... licensure, a team of leading scientists said. ... for regulatory review of dengue vaccines, while plans are ...
... from the University at Buffalo could lead to new solutions ... from drinking water. To the naked eye, both water ... are measured by the nanometer, a unit of length about ... , But at the microscopic level, the two actually differ ...
Cached Biology Technology:Reportlinker Adds Global Biotechnology Reagents Industry 2Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines 2Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines 3A nano-solution to global water problem: Nanomembranes could filter bacteria 2
(Date:7/10/2014)... ant Anoplolepis gracilipes is ranked amongst the top ... ecological impacts on islands. A new study published in the ... assesses the effects and dangers of the introduction of the ... palm forest of the Valle de Mai, a UNESCO World ... Valle de Mai is a unique ecosystem containing many endemic ...
(Date:7/9/2014)... Philadelphia, PA, July 10, 2014 Inflammatory diseases ... same patient, complicating treatment because a medication effective ... such example is the anti-arthritic medication dexamethasone, which ... disease. A study in the August issue of ... the effects of a new class of anti-arthritic ...
(Date:7/9/2014)... Bacteria found in the bladders of healthy women ... form of incontinence, according to researchers from Loyola ... These findings, published July 9, 2014, in the ... , suggest that bacterial communities may play a ... incontinence (UUI) is a common, yet poorly understood, ...
Breaking Biology News(10 mins):Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2
... know - are drawing up gold particles from the earth via ... from CSIRO made the discovery and have published their findings in ... a hydraulic pump its roots extend tens of metres into ... gold is likely to be toxic to the plant, it,s moved ...
... , Oct. 23, 2013 Increasing awareness ... commercial biometrics market. While historically the adoption of ... recent years have witnessed considerable demand for applications ... finance. Iris and face recognition algorithms have undergone ...
... SALT LAKE CITYFor people with a family history of ... to 10 percent of colorectal cancers could be missed ... is the third most common cancer in the United ... population-based study to date, researchers from Huntsman Cancer Institute ...
Cached Biology News:There's gold in them thar trees 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 3Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 4Colon cancer screening guidelines may miss 10 percent of colon cancers 2
... 20 years of expertise in the field ... offers the most powerful systems on the ... 40 000 in-microplate tests requiring incubation and ... different modules (such as worktable shaker incubators, ...
... or Isolated Sequence) siRNA Test System is ... evaluation of a potential of any DNA ... for RNA interference (RNAi). Current computer-based RNAi ... the probability of selected sequence to be ...
... pre-validated SNP sequencing services ... within 93 genes including ... more than 80 tyrosine ... were developed and validated ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
Biology Products: